The drug Esmya can mean women suffering from uterine fibroids, which affect four in 10 women, don’t have to have hysterectomies. According to a new study, nearly half of women were unaware that excessive menstrual bleeding is one of the main symptoms of fibroids, a debilitating condition where benign lumps develop in the womb. The research also found that almost 60 per cent were unsure what fibroids were, and over half were unaware that fibroids can cause fertility problems and miscarriages. Uterine fibroids affect 40 in every 100 women at some time in their life, and can affect work, relationships with partners and also cause depression. Despite this, women often wait up to five years before speaking to a doctor about their symptoms. The research was carried out by www.fibroidsconnect.co.uki, a website developed by Esmya manufacturer Gedeon Richter, to highlight the lack of understanding and awareness. Women’s health specialist Dr Rosemary Leonard said: “Like many conditions, the earlier fibroids are diagnosed the easier they can be to treat, so it’s important not to ignore potential warning signs. There are different treatment options available, some of which do not involve a hysterectomy or other major surgery that can affect fertility, which is important for those women who still want children.” The new treatment, Esmya, is a once-daily tablet, authorised by the European Commission to be taken on an intermittent basis, so women could potentially avoid surgery.

Generic pic of woman with fibroids

Generic pic of woman with fibroids

0
Have your say

A new treatment for a painful gynaecological condition is now available for women in Leeds.

Treatment for painful condition affecting Leeds women

Queen Elizabeth II at the launch at Buckingham Palace, London of The Queen's Baton Relay for the XXI Commonwealth Games being held on the Gold Coast in 2018. PRESS ASSOCIATION Photo. Picture date: Monday March 13, 2017. See PA story ROYAL Commonwealth. Photo credit should read: Toby Melville/PA Wire

Week Ahead: What will make the headlines this week (beginning April 17, 2017)